Hepatitis B Foundation strongly supports Congressional letters urging Biden administration to end discriminatory military policy <<Click here>>

Welcome to our Liver Cancer Connect Program



Find Clinical Trials Near Me!

hepbfoundation livercancer banner 1


If you or someone you know is living with liver cancer, American Liver Foundation's 3rd annual "The Educated Patient: A Liver Cancer Conference" is on October 7th and 8th. The virtual event will feature presentations from leading experts in the field and will enable patients and family members to feel more prepared in taking an active role in the disease management process. Register today: https://liver.news/lcc22

Check out this video with a liver cancer survivor on Closing the Care Gap!

This panel discussion features someone with lived experience of liver cancer and his wife in conversation with researchers and patient advocates. The discussion highlights what is missing in order to improve the lives of people diagnosed with HCC. Check it out today!

Watch our latest webinar! In it, panelists discuss conclusions & insights from a recent project to identify & close disparities in hepatitis B & liver cancer knowledge and screening rates among highly impacted communities around the US. Check it out today!

webinar series

newly diagnosed

Liver Cancer Connect is a dedicated program of the Hepatitis B Foundation that was created to provide individuals and families with the information and support they need when facing the challenge of primary liver cancer. Although this is a serious diagnosis, there is good reason to have hope because of the many advances made in the early detection, management and treatment of liver cancer.

In the News

New Study Shows Options for Older Patients With Liver Cancer

Case 3: Novel Frontline Combination Strategies for Unresectable HCC (Video)

Current and Future Immunotherapy Approaches for HCC: Evidence, Guidance, and Resources (Podcast)

Elevar Therapeutics and Hengrui Pharma Announce Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival in Patients With Unresectable Hepatocellular Carcinoma (Phase III Trial)

Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma

Cabozantinib Plus Atezolizumab in Advanced Hepatocellular Carcinoma and the Role of Adjuvant Antiviral Therapy

AACR Report Finds Racial and Ethnic Minorities Continue to Shoulder a Disproportionate Burden of Cancer

Assessing the Risk of HCC for Hepatitis B Treatments

Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of HCC

Perioperative Opdivo Alone, in Combination with Yervoy, Safe for Patients with HCC

Study Uncovers New Treatment Approaches for Liver Cancer Patients

REACH-B Score for Hepatocellular Carcinoma

Bringing Early Cancer Detection to the Masses

New Guidelines Clarify Use of Systemic Therapy in Advanced HCC

NUS Scientists Discover New Clues to Liver Cancer Progression

How Have Hepatocellular Carcinoma Treatments Improved?

ASTRO Issues Clinical Guideline on External Beam Radiation Therapy for Primary Liver Cancers

What Cancer Survivors Should Know About Their Mental Health

Neoadjuvant Immunotherapy for Resectable Hepatocellular Carcinoma

Treatment of Hepatocellular Carcinoma in Sub-Saharan Africa: Challenges and Solutions

Kintor Initiates Dosing in Phase II Hepatocellular Carcinoma Therapy Trial

What Gastroenterologists Need to Know About New Guidelines on Systemic HCC Therapy

Phase II Trial of GT90001 Plus Nivolumab Enrolls First Patient with Advanced HCC

EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma

About Herbs, Botanicals, and Other Products (from Memorial Sloan Kettering Cancer Center)

Cancer Burden Facing Asian Americans Partly Caused By Racism

New Point-of-Care Ultrasound Tool May Aid Detection of Liver Stiffness in Obese Patients

Researchers Identify a New tsRNA in Blood to Improve Liver Cancer Diagnosis

The International Liver Cancer Network (ILCN), of which HBF is a member, released a white paper promoting increased effort to improve prevention, early detection and access to care for liver cancer.

After FDA Evaluation, BMS Withdraws Opdivo For Liver Cancer Treatment in Patients Previously Treated with Sorafenib in the U.S.

FDA Grants “Orphan Drug” Designation to Chemotherapeutic Uttroside-B for Use in Patients with HCC. The drug is in pre-clinical testing.

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic Hepatocellular Carcinoma (ASCOPost, May 2020)

Atezolizumab Combination Improves Survival in HCC (Cancer Letter, May 2020)

COVID-19: What People With Cancer Need to Know (Cancer.net, June 2020)

U.S. FDA Approves Opdivo® (Nivolumab) + Yervoy® (Ipilimumab) for Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

U.S. Food and Drug Administration (FDA) Has Granted Breakthrough Device Designation to the Elecsys® GALAD Score to Help Diagnose HCC

Pan Tumor Clinical Trial Is Actively Recruiting to Investigate the Effects of Nivolumab When Given Under the Skin With or Without rHuPH20. Learn more! 

FDA Has Approved Cabozantinib (CABOMETYX, Exelixis, Inc.) for Patients with Hepatocellular Carcinoma Who Have Been Previously Treated with Sorafenib

DNA Search Finds People Resistant to Liver Disease. Can We Mimic This Effect with a Drug? Regeneron and Alnylam Pharmaceutical to Partner  

Newly Discovered Anti-Cancer Protein LHPP Prevents Uncontrolled Proliferation of Cancer Cells in the Liver and May Serve as a Biomarker for the Diagnosis & Prognosis of Liver Cancer 

Get Connected

square facebook 512Twitter icon horizontal2